🟢 Edesa Biotech is trading 5% up today after FDA clears IND for EB06 vitiligo study

Edesa Biotech is trading at $2.79, up 5.09%, after FDA clearance of the IND for its Phase 2 EB06 vitiligo study.

• The company announced the clearance October 15, allowing recruitment to expand into the United States.
• U.S. sites are expected to begin enrolling next quarter, with topline results anticipated in Q4 2027.
• This is clearance to conduct the study, not FDA approval of a treatment; broader biotech strength provided additional support.